ERBB2 and cancer: Final report of phase I/II clinical trials (NCT00841399 and NCT00584789) of the E75 vaccine along with booster immunizations significantly mitigated cancer recurrence in 95.2% of participants with HER2-expressing high-risk breast cancer [201].